Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Executive summary

Budget impact of Barzolvolimab

2 evidence topics · 18 sources

Summary: price status and comparator prices
  • The company anticipates a BLA submission to the FDA for barzolvolimab in CSU in 2027. No published price and no budget impact model for barzolvolimab were found.
  • Remibrutinib (Rhapsido): list (or wholesale) price of $4,521 per package (30-day supply, 60 tablets) as of January 7, 2026.
  • Dupilumab (Dupixent): $4,193.03 per 4-week supply, defined as two injections, with pricing as of January 1, 2026. The Oregon PDAB review lists a 2025 WAC of $3,993 per 30-day supply for 300 mg every 2 weeks.
  • Omalizumab (Xolair): Genentech states a current list price (WAC) of approximately $30,000 - $60,000 annually. The Oregon PDAB review states a WAC of approximately $1472.76 per unit at the end of 2025, an average annual unit WAC increase of 4.9 percent between 2019 and 2025, and a 2025 WAC of $5,891 per 30-day supply for 600 mg every 1 month.
  • The draft AAAAI/ACAAI joint task force guideline lists direct prices as of December 2025 of $1475 per month for omalizumab, $4,193.03 per carton for dupilumab, and $4,424.01 per bottle of 60 tablets for remibrutinib.
  • In the 2024 Oregon All Payer All Claims data, 901 enrollees had 8,833 Xolair claims, with approximately $19.5 million in total gross payer spending and approximately $21,618 in annual gross payer spending per enrollee.
  • The Oregon PDAB review states that omalizumab biosimilar competition became available in 2026 and that Xolair was selected for the third cycle of the Medicare Drug Price Negotiation Program, with any negotiated Maximum Fair Price scheduled to take effect January 1, 2028. Healio reports that the biosimilar Omlyclo is commercially available in the U.S.
  • Celldex states a CSU prevalence of 0.5-1.0% of the total population, or up to approximately 1 to 3 million patients in the United States, and that approximately 50% of patients with CSU achieve symptomatic control with antihistamines. Its topline presentation states that 25-35% of patients with CSU are assessed as severe and projects that the second-line advanced therapy market will eclipse the first-line market.
Summary: cost-effectiveness analyses and health technology assessments of comparators
  • Omalizumab, NICE TA339: the company's revised deterministic base case with the patient access scheme gave an ICER of £27,469 per QALY gained (around £26,000 per QALY gained in severe disease at baseline). NICE recommends omalizumab for severe CSU only when severity is assessed objectively, for example a UAS7 of 28 or more, and when it is stopped at or before the fourth dose if the condition has not responded.
  • Omalizumab versus standard of care, UK societal perspective (Novartis-funded): deterministic base-case ICER of £3183 over a 20-year time horizon, with productivity inputs as key model drivers.
  • Omalizumab versus standard of care, Netherlands societal perspective: ICER of €17 502 per QALY gained, and €85 310 per QALY when productivity costs were discarded.
  • Omalizumab versus standard treatment, China, patient perspective: ICER of ¥160,411/QALY.
  • Remibrutinib with cetirizine versus cetirizine alone, US healthcare sector perspective (conference poster): ICER of $3,208,966 per QALY over 10 years and $232,084 per QALY over 24 weeks; remibrutinib was not cost-effective at a willingness to pay of $150,000 per QALY.
  • Remibrutinib, NICE draft guidance (September 2026): remibrutinib “should not be used” for CSU inadequately controlled by H1-antihistamines in adults; the draft states that it is not possible to determine the most likely cost-effectiveness estimates, and the list price in the company submission is confidential.
  • A Canadian prevalence-based model (conference poster) estimated that remibrutinib coverage would reduce the productivity burden of symptomatic CSU by 69% overall.
  • An omalizumab biosimilar budget impact model across 23 European countries reported omalizumab expenditures exceeding €787 million in 2024 (all indications) and projected €40 million in first-year savings at a 30% discounted biosimilar price.
  • No cost-effectiveness analysis of dupilumab in CSU was found.